Immunocore (NASDAQ:IMCR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Immunocore (NASDAQ:IMCR) from a hold rating to a buy rating in a report published on Saturday morning.

IMCR has been the subject of several other reports. Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a research report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of Immunocore in a report on Wednesday, October 22nd. Wells Fargo & Company initiated coverage on shares of Immunocore in a research report on Friday, October 31st. They issued an “overweight” rating and a $60.00 price objective on the stock. Guggenheim initiated coverage on shares of Immunocore in a research report on Thursday, September 18th. They set a “neutral” rating for the company. Finally, Zacks Research lowered shares of Immunocore from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 4th. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $61.00.

Immunocore Price Performance

Shares of NASDAQ:IMCR opened at $35.00 on Friday. The company has a 50 day moving average of $33.89 and a 200 day moving average of $33.23. The company has a current ratio of 6.00, a quick ratio of 5.97 and a debt-to-equity ratio of 0.99. The stock has a market cap of $1.76 billion, a P/E ratio of -61.40 and a beta of 0.78. Immunocore has a 12 month low of $23.15 and a 12 month high of $39.33.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.30) by $0.32. The firm had revenue of $135.80 million during the quarter, compared to the consensus estimate of $137.29 million. Immunocore had a negative net margin of 7.70% and a negative return on equity of 7.67%. The business’s quarterly revenue was up 29.2% compared to the same quarter last year. During the same period last year, the firm earned $0.17 EPS. As a group, sell-side analysts forecast that Immunocore will post -0.94 EPS for the current fiscal year.

Insider Buying and Selling

In other Immunocore news, insider David M. Berman sold 22,532 shares of Immunocore stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $35.67, for a total transaction of $803,716.44. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 10.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Immunocore

Several institutional investors and hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC lifted its stake in Immunocore by 51.6% in the third quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock worth $33,000 after purchasing an additional 311 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in shares of Immunocore by 4,696.3% in the second quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company’s stock worth $41,000 after buying an additional 1,268 shares during the period. Elevation Point Wealth Partners LLC bought a new stake in shares of Immunocore in the 2nd quarter valued at about $42,000. Osaic Holdings Inc. lifted its stake in shares of Immunocore by 117.4% in the 2nd quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock valued at $97,000 after acquiring an additional 1,700 shares during the last quarter. Finally, State of Tennessee Department of Treasury purchased a new stake in Immunocore during the 2nd quarter valued at about $132,000. Institutional investors own 84.50% of the company’s stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.